Riskpilot← Back to searchSign inGet full accessSCLEROMAX AS
ASActiveOrg 828331132Fredriksborgveien 50A, 0286 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20210 employees
Revenue 2025
NOK 0
EBITDA margin
—
+9% vs 2024
Equity ratio
-4083.3%
Financial strength
Net profit 2025
NOK -29K
+10% vs 2024
| Revenue | NOK 0 | — |
| EBITDA | NOK -29K | +9% |
| Net profit | NOK -29K | +10% |
| Total assets | NOK 2K | +52% |
| Equity | NOK -92K | -45% |
| Employees | 0 | — |
Legal name
SCLEROMAX AS
Org number
828331132
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14. desember 2021
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets leder eller daglig leder hver for seg. To styremedlemmer i fellesskap.
Company purpose
Konsulenttjenester innen medisin, biomedisins forskning og patentering, redaktørvirksomhet og artikkelforfatterskap, samt handel og investering i næringsvirksomhet, herunder aksjer og andeler og deltagelse i andre selskaper med lignende virksomhet.
Address
Fredriksborgveien 50A, 0286 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −6 | −29 | −27 | −31 | −29 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −6 | −29 | −27 | −31 | −29 |
| Net financials | 0 | −0 | 0 | −0 | 0 |
| Profit before tax | −6 | −29 | −27 | −32 | −29 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −6 | −29 | −27 | −32 | −29 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 24 | 3 | 5 | 1 | 2 |
| Equity | 24 | −5 | −32 | −64 | −92 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 8 | 37 | 65 | 95 |
| Total debt | 0 | 8 | 37 | 65 | 95 |
EBITDA margin
-2865400.0%
This company
15.8%
Market median
-18135543% vs market
20212025
Equity ratio
-4083.3%
This company
38.2%
Market median
-10789% vs market
20212025
Return on equity
-2865300.0%
This company
18.4%
Market median
-15572383% vs market
20212025
Net profit margin
-2865300.0%
This company
8.1%
Market median
-35374174% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
1.02×
This company
0.62×
Market median
-65% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AO Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Chairman | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SCLEROMAX AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ansgar Oddne Aasen | Chief Executive Officer | 0 companies |
| Fredrik Eitzen | Chairman | 0 companies |
| Jan Stykket | Board of Directors | 0 companies |